Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Chantix, a quit...

    Chantix, a quit smoking drug trial data fails to impress FDA

    Written by savita thakur thakur Published On 2016-09-14T14:28:58+05:30  |  Updated On 14 Sept 2016 2:28 PM IST
    Chantix, a quit smoking drug trial data  fails to impress  FDA

    Pfizer Inc's (PFE.N) trial data on Chantix, a drug to help people quit smoking, failed to impress U.S. Food and Drug Administration scientists, in a blow to the company's attempts to have a serious warning removed from the drug's label.


    The FDA staff, in a preliminary review, expressed concerns about the collection and interpretation of data from a post-marketing study on the controversial drug.


    Pfizer has been trying to have the "black box" warning - which warns of psychiatric risks including suicidal thoughts, hostility and agitation - removed from the drug's label.


    In March 2015, the FDA left the warning on the label, following the recommendation of an advisory committee to wait for the outcome of the study in more than 8,000 adult smokers.


    Results from the study, which compared Chantix or GlaxoSmithKline Plc's (GSK.L) Zyban with a placebo or a nicotine patch in smokers with and without a history of psychiatric disorders, showed that the drug did not significantly increase the incidence of serious neuro psychiatric side effects.


    However, FDA staff disputed the results, flagging inconsistencies in data collection and characterization of the severity of some side-effects.


    These factors could have led to biased results, they said, ahead of a meeting of independent advisers on Wednesday.


    The advisers will discuss the trial findings and decide whether the warning should be removed. The FDA is not obligated to follow the panel's recommendations, but it usually does.


    James Rusnak, chief development officer of Pfizer's cardiovascular metabolic unit, said there were bound to be variations in investigators' judgment within the boundaries of the trial protocol, just like in the case of doctors in clinical practice.


    "Ultimately, what was reported as an adverse event, was determined based upon the investigator's local determination of the subject presenting in front of them," he said.


    Any subjectivity in investigator's judgment would be spread across the four treatment groups and not be limited to Chantix, Rusnak noted.


    In May, European regulators lifted a warning on the drug, sold under the brand name Champix in Europe, based on the results of a large study.


    Investors were betting big on the drug when Pfizer launched it in 2006, but reports of mental health problems in users led to the FDA imposing the black box warning three years later.


    Chantix, which loses patent exclusivity in four years, generated global sales of $671 million in 2015.

    Chantixcontroversial drugGlaxoSmithKlineGSKJames RusnakPfizerpsychiatric disordersUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok